JF
CCCC icon

Jump Financial’s C4 Therapeutics CCCC Stock Holding History

Jump Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-134,636
Closed -$767K – 1680
2024
Q3 		$767K Sell
134,636
-88,564
-40% -$533K 0.02% 916
2024
Q2 		$1.03M Buy
223,200
+106,693
+92% +$636K 0.02% 801
2024
Q1 		$952K Buy
+116,507
New +$903K 0.03% 831
2023
Q3 		– Sell
-17,915
Closed -$49.3K – 1877
2023
Q2 		$49.3K Buy
+17,915
New +$57.6K ﹤0.01% 1724
2023
Q1 		– Sell
-36,000
Closed -$212K – 1633
2022
Q4 		$212K Buy
+36,000
New +$298K 0.01% 1254
2022
Q3 		– Sell
-18,721
Closed -$141K – 1623
2022
Q2 		$141K Buy
18,721
+2,921
+18% +$25.7K 0.01% 1385
2022
Q1 		$383K Sell
15,800
-18,189
-54% -$442K 0.02% 942
2021
Q4 		$1.09M Sell
33,989
-5,711
-14% -$226K 0.07% 365
2021
Q3 		$1.77M Buy
+39,700
New +$1.7M 0.13% 175

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jump Financial's CCCC Position: Q4 2024 in Review

Jump Financial sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 134,636 shares — an estimated $767K sold.

Jump Financial first reported a position in CCCC in Q3 2021 and held it in 9 quarters. The position peaked at $1.77M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Jump Financial reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jump Financial sold 134,636 C4 Therapeutics shares in Q4 2024, an estimated $767K.
  • Jump Financial first reported a position in C4 Therapeutics in Q3 2021 and held it in 9 quarters.
  • Jump Financial's C4 Therapeutics position peaked at $1.77M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.